- Details
- Aditya Bagrodia hosts Daniel Spratt to discuss the complexities of gene expression classifiers in prostate cancer. Dr. Spratt's team conducted a study involving over 50,000 patients to evaluate the interchangeability of three major gene classifiers: Decipher, Oncotype, and Polaris. Contrary to common belief, the study reveals that these tests are not functionally interchangeable, showing only mode...
|
- Details
- Daniel Spratt engages with Amar Kishan about the role of transcriptomic profiling and PSMA PET imaging in prostate cancer. Dr. Kishan discusses a study involving 18 trials and 12,500 patients, which suggests that extra-prostatic disease is often the driver of distant metastasis in high-risk patients. The study also explores the correlation between Decipher® scores and the risk of upstaging on PSMA...
|
- Details
- Phillip Koo interviews Ragu Ratnakumaran about the analysis of the PACE-B study. The study is a phase III international randomized control trial involving 874 patients with low to intermediate-risk prostate cancer. Dr. Ratnakumaran's analysis focuses on the association between acute and late genitourinary and gastrointestinal toxicities in two radiotherapy treatment arms: conventional or moderatel...
|
- Details
- In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between increased...
|
- Details
- John Davis, Professor of Urology, discusses the new Journal of Urology Open Plus with Phillip Koo. The journal aims to provide fully gold open access, making research freely accessible to all. It addresses the need for easily accessible research, especially for publicly funded projects. The concept of cascading allows submissions to be considered across multiple journals within the AUA. The focus...
|
- Details
- Matt Cooperberg interviews Sigrid Carlsson, Director of Research at MSK for Urology, on the evolution of prostate cancer screening policy and ongoing innovative trials. Carlsson, an integral member of the AUA's screening guideline panel, highlights the transition from the traditional DRE and PSA tests to a new era of risk-stratified screening, aiming to optimize the benefits of PSA testing while m...
|
- Details
- Matthew Cooperberg and Daniel Lin discuss the update to the American Urological Association's (AUA) prostate cancer screening guideline in this discussion. They highlight the collaborative effort involved in the guideline update, involving a large group of experts and reviewers. They compare the AUA's process with that of the National Comprehensive Cancer Network (NCCN) and discuss the systematic...
|
- Details
- Ashley Ross and Jim Hu discuss the use of genomic classifiers, specifically the Decipher Genomic Classifier, in the management of localized prostate cancer. They review its performance in larger datasets and its association with prostate cancer outcomes. The conversation also delves into the use of the Decipher Prostate Biopsy Test in men with favorable risk disease undergoing conservative managem...
|
- Details
- In this conversation, Alicia Morgans speaks with Professor David Penson about the ProtecT trial and its implications for clinical practice. The study found no difference in outcomes between surgery, radiation, and conservative management in prostate cancer patients after 10 years of follow-up. However, a recent 15-year follow-up has revealed some new findings. The cohort of patients enrolled in th...
|
- Details
- In a discussion between Alicia Morgans and Jonathan Shoag, the importance of PSA screening for prostate cancer is emphasized, particularly considering its controversial history. Introduced over 30 years ago, PSA screening initially led to an increased incidence of prostate cancer diagnoses without a corresponding decrease in mortality. This led to skepticism and a backlash against the procedure, r...
|
